Kelun-Biotech partner launches phase 2 asthma trial for antibody therapy

Published 23/07/2025, 14:30
Kelun-Biotech partner launches phase 2 asthma trial for antibody therapy

CHENGDU, China - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKEX:6990), a prominent biotechnology player with a market capitalization of $11 billion and strong revenue growth of 25.48% in the last twelve months, announced Wednesday that its partner Windward Bio AG has initiated the Phase 2 POLARIS clinical study to evaluate SKB378/WIN378 for asthma treatment.

The global, randomized, double-blind, placebo-controlled study will assess the dosing, safety, and efficacy of the long-acting monoclonal antibody in asthma patients, with initial data expected by mid-2026.

SKB378/WIN378 is a recombinant fully human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a cytokine involved in various immunological conditions including asthma and chronic obstructive pulmonary disease (COPD).

The antibody has been engineered for extended half-life and is administered subcutaneously. A completed Phase 1 trial confirmed its extended dosing potential with a low rate of antidrug antibodies and favorable safety profile.

In January 2025, Kelun-Biotech and Harbour BioMed granted Windward Bio exclusive license rights for SKB378/WIN378 globally, excluding Greater China and several Asian countries. That same month, China’s National Medical Products Administration approved an Investigational New Drug application for the antibody’s use in COPD treatment. The company’s stock has shown remarkable performance, delivering a 148.52% return over the past year and currently trading near its 52-week high of $50.73.

InvestingPro analysis reveals 15 additional investment insights for Kelun-Biotech, including detailed financial health metrics and growth indicators.

Additional clinical trials for COPD are planned for 2026, according to the company’s press release statement.

Windward Bio, a clinical-stage biotechnology company focused on immunological conditions, launched earlier this year with a $200 million Series A funding round.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.